Premium
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
Author(s) -
Gerecitano John,
Portlock Carol,
Moskowitz Craig,
Hamlin Paul,
Straus David,
Zelenetz Andrew D.,
Zhang Zhigang,
Dumitrescu Otilia,
Sarasohn Debra,
Lin Dorothy,
Pappanicholaou Jennifer,
Cortelli Barbara M.,
Neylon Ellen,
Hamelers Rachel,
Wright John,
O’Connor Owen A.
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07775.x
Subject(s) - bortezomib , mantle cell lymphoma , medicine , follicular lymphoma , schedule , oncology , lymphoma , multiple myeloma , computer science , operating system
Summary Twice‐weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0·02) with no complete remissions (CR) (compared with 18% CR for the twice‐weekly schedule). Progression‐free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice‐weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.